8-K: Plus Therapeutics Q2 2025: Strong Cash, CNSide Launch, REYOBIQ Progress

Plus Therapeutics reports improved Q2 2025 financial results, driven by non-operating income, alongside significant advancements in its REYOBIQ clinical trials and the commercial launch of its CNSide diagnostic platform.

Summary

• Net income for the second quarter of 2025 was $5.2 million, or $0.02 per share, a significant improvement compared to a net loss of $2.9 million, or $(0.45) per share, for the same quarter in 2024, primarily due to $6.5 million of pre-tax income from the change in fair value of derivative instruments.
• Cash and investments balance increased to $6.9 million at June 30, 2025, from $3.6 million at December 31, 2024.
• Total operating loss for the second quarter of 2025 decreased to $1.5 million compared to $3.7 million in the same quarter of 2024, attributed to a heightened focus on operational cost control.
• Grant revenue recognized in the second quarter of 2025 was $1.4 million, up from $1.3 million in the same quarter of 2024, representing CPRIT's share of costs for REYOBIQ platform advancement.
• Initiated and treated the first two patients in the ReSPECT-LM dose optimization trial for REYOBIQ, evaluating multiple-dose regimens for leptomeningeal metastases.
• Received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for REYOBIQ for the treatment of pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma, funded by a $3 million grant from the Department of Defense.
• The CNSide cerebral spinal fluid (CSF) assay platform and testing services commercially launched in Texas in August 2025, with an initial focus on National Cancer Institute Designated Cancer Centers.
• Received notice of an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of the previously awarded $17.6 million grant.
• Completed a comprehensive restructuring of the March 2025 $15 million equity financing on June 17, 2025, simplifying the company's capital structure.
• Added industry veteran Kyle Guse to the Board of Directors, bringing 30 years of professional experience.

Sentiment

Score: 7

Explanation: The company reported a positive net income for Q2 2025, albeit largely due to non-operating income from derivative instruments. However, it also demonstrated strong operational progress with reduced operating loss, increased cash, significant advancements in its REYOBIQ clinical programs (dose optimization trial, FDA clearance for pediatric IND), and the commercial launch of its CNSide diagnostic platform. These operational and strategic milestones indicate positive momentum despite the underlying six-month net loss.

Positives

• Net income of $5.2 million in Q2 2025, a substantial improvement from a $2.9 million net loss in Q2 2024.
• Cash and investments balance increased to $6.9 million at June 30, 2025, from $3.6 million at December 31, 2024, indicating improved liquidity.
• Operating loss reduced to $1.5 million in Q2 2025 from $3.7 million in Q2 2024, reflecting enhanced operational cost control.
• Received an advance payment of $1.6 million from CPRIT, contributing to funding for the REYOBIQ platform.
• Successful restructuring of the March 2025 $15 million equity financing, simplifying the capital structure.
• Initiated and treated the first two patients in the ReSPECT-LM dose optimization trial for REYOBIQ, demonstrating clinical progress.
• FDA clearance of the IND application for REYOBIQ in pediatric HGG and ependymoma, supported by a $3 million DoD grant, expanding the potential market.
• Commercial launch of the CNSide CSF assay platform and testing services in Texas in August 2025, targeting a U.S. total addressable market estimated at $6 billion for the first test.
• Addition of industry veteran Kyle Guse to the Board of Directors, strengthening governance and expertise.

Negatives

• Net income for Q2 2025 was primarily driven by a $6.5 million pre-tax income from the change in fair value of derivative instruments, which is a non-operating and potentially volatile item, rather than core business operations.
• The company reported a net loss of $12.25 million for the six months ended June 30, 2025, indicating continued overall unprofitability.
• Research and development expenses decreased to $1.246 million in Q2 2025 from $2.773 million in Q2 2024, which, while contributing to reduced operating loss, could also suggest a slowdown in R&D investment.

Risks

• Ability to maintain the listing of common stock on Nasdaq.
• Risks related to a halt in trading or delisting of common stock on Nasdaq.
• The early stage of product candidates and therapies.
• Uncertainties relating to the clinical trials of product candidates and therapies, including safety and efficacy outcomes.
• Liquidity and capital resources and the ability to raise additional cash to fund operations and development.
• The outcome of partnering/licensing efforts.
• Risks associated with laws or regulatory requirements applicable to the company.
• Market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field.
• Ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms.
• Challenges associated with radiotherapeutic manufacturing, production, and distribution capabilities necessary to support clinical trials and any commercial level product demand.
• Material security breach or cybersecurity attack affecting operations or property.

Future Outlook

The company intends to expand its CNSide testing services and broaden regional availability over the next 12 months, following its commercial launch in Texas. It will also continue active enrollment in the REYOBIQ dose optimization trial and present updated clinical trial results at upcoming conferences.

Management Comments

• "The second quarter of 2025 marked steady execution and progress on our key strategic initiatives: clinical development of our radiotherapeutic and the advancement of our diagnostic platform technologies toward commercialization."
• "New data announcements on our REYOBIQ CNS cancer radiotherapeutic clinical trials continue to demonstrate favorable safety and efficacy signals, facilitating active enrollment on our dose optimization trial."
• "Furthermore, the recently announced launch of the CNSide cerebral spinal fluid (CSF) assay platform and testing services in Texas with initial focus on national cancer centers validates the clinical need for our diagnostic management tool."
• "We intend to expand our testing services and broaden the regional availability of CNSide over the next 12 months."

Industry Context

The company operates in the highly specialized and challenging field of central nervous system (CNS) cancers, including leptomeningeal metastases (LM) and high-grade glioma (HGG). It addresses a significant unmet medical need, as CNS metastases affect up to 30% of adult cancer patients, and current diagnostic methods like CSF cytology are over a century old and offer suboptimal sensitivity. The estimated total addressable market for the CNSide CSF Tumor Cell Enumeration (TCE) test is $6 billion in the U.S., highlighting the substantial market opportunity for improved diagnostics in this area. The development of targeted radiotherapeutics like REYOBIQ aims to provide more effective and safer treatment options compared to existing therapies.

Comparison to Industry Standards

• The current standard of care for CNS Mets diagnosis, CSF cytology, was developed over a century ago and offers suboptimal test sensitivity, leading to missed or delayed diagnosis and treatment. CNSide aims to provide a superior diagnostic solution.
• Approximately half of patients with CSF metastases currently receive only palliative care or hospice, indicating a significant unmet need for effective diagnostic and treatment options that REYOBIQ and CNSide aim to fulfill.
• REYOBIQ is positioned as a novel injectable radiotherapy with the potential to reduce off-target risks and improve outcomes for CNS cancer patients compared to currently approved therapies, by delivering a more targeted and potent radiation dose.
• The company estimates the total addressable market for its first CNSide test, CSF Tumor Cell Enumeration (TCE), to be $6 billion in the U.S., based on published CNS cancer incidence data, third-party projections of test utilization, and established market benchmarks.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Improved cash position, reduced operating loss, and simplified capital structure could be positive. However, the Q2 net income is largely non-operational, and a six-month net loss persists. Clinical and commercial progress offers future growth potential.
• Patients: Advancement of REYOBIQ clinical trials and FDA clearance for pediatric indications offer potential new treatment options for difficult-to-treat CNS cancers. The launch of CNSide provides a new diagnostic tool for leptomeningeal metastases.
• Investment Professionals: The filing provides key financial metrics and strategic updates on clinical development and commercialization, aiding in valuation and risk assessment.
• Regulatory Authorities: FDA clearance of IND application demonstrates compliance and progress in drug development.
• Employees: Continued progress in clinical trials and commercialization efforts supports the company's long-term viability and mission.

Next Steps

• Expand CNSide testing services and broaden regional availability over the next 12 months, following the Texas launch.
• Add three additional CNS assays to the CNSide platform in the coming months.
• Continue active enrollment in the ReSPECT-LM dose optimization trial for REYOBIQ.
• Give an oral presentation of ReSPECT-LM clinical trial results and a sponsored educational symposium at the SNO/ASCO CNS Metastases Conference on August 14-16, 2025.
• Showcase two presentations on CNSide at the SNO/ASCO CNS Metastases Conference on August 14-16, 2025.

Key Dates

Recommendation

While Plus Therapeutics reported a positive net income for Q2 2025, this was primarily driven by a non-recurring $6.5 million pre-tax income from derivative instruments, rather than core operational profitability. However, the company demonstrated strong operational improvements with a reduced operating loss and a significantly improved cash and investments balance. Crucially, the company achieved substantial strategic milestones, including the commercial launch of its CNSide diagnostic platform in Texas (targeting a $6 billion market), the initiation of a dose optimization trial for REYOBIQ, and FDA clearance for a pediatric IND for REYOBIQ. These advancements in both diagnostics and therapeutics, coupled with a simplified capital structure and a new board member, indicate positive momentum and future growth potential. Given the early stage of its product candidates, the reliance on non-operating income for Q2 profitability, and the inherent risks in clinical development, a 'hold' recommendation is appropriate. Investors should monitor the sustained commercial traction of CNSide and further clinical data from REYOBIQ trials for clearer long-term prospects.

Keywords

Plus Therapeutics, PSTV, REYOBIQ, CNSide, Leptomeningeal Metastases, LM, High-Grade Glioma, HGG, Ependymoma, Radiotherapeutics, CNS Cancers, CSF Assay, Clinical Trials, FDA Clearance, CPRIT Grant, Nasdaq, Biotechnology, Oncology, Diagnostics, Pharmaceuticals